Akero Therapeutics, Inc. the people running the company have only been selling lately: one insider unloaded about $1.6 million of stock over 12 months, with no open-market purchases.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 14, 2025 | Cheng Andrew | CEO | Sell | 30,000 | $53.98 | $1.6M | SEC |
| Oct 9, 2025 | Rolph Timothy | Executive Officer | Sell | 11,463 | $46.01 | $527K | SEC |
| Oct 9, 2025 | Rolph Timothy | Executive Officer | Sell | 1,037 | $46.82 | $49K | SEC |
| Oct 3, 2025 | Young Jonathan | COO | Sell | 8,299 | $47.64 | $395K | SEC |
| Oct 3, 2025 | Young Jonathan | COO | Sell | 4,201 | $47.98 | $202K | SEC |
| Sep 12, 2025 | Young Jonathan | COO | Sell | 586 | $43.02 | $25K | SEC |
| Sep 12, 2025 | Yale Catriona | Executive Officer | Sell | 659 | $43.02 | $28K | SEC |
| Sep 12, 2025 | White William Richard | CFO | Sell | 659 | $43.02 | $28K | SEC |
| Sep 12, 2025 | Rolph Timothy | Executive Officer | Sell | 553 | $43.02 | $24K | SEC |
| Sep 12, 2025 | Cheng Andrew | CEO | Sell | 1,796 | $43.02 | $77K | SEC |
| Sep 12, 2025 | Cheng Andrew | CEO | Sell | 7,317 | $44.00 | $322K | SEC |
| Sep 12, 2025 | Cheng Andrew | CEO | Sell | 22,525 | $42.99 | $968K | SEC |
| Sep 12, 2025 | Cheng Andrew | CEO | Sell | 158 | $44.62 | $7K | SEC |
| Sep 10, 2025 | Rolph Timothy | Executive Officer | Sell | 34 | $44.88 | $2K | SEC |
| Sep 10, 2025 | Rolph Timothy | Executive Officer | Sell | 12,466 | $44.17 | $551K | SEC |
In the last 12 months Akero Therapeutics, Inc. insiders made open-market purchases worth about $0 and sales worth about $1.6 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in AKRO was filed on 2025-10-14.
No congressional trades in AKRO were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).